Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Lyra Therapeutics, Inc. (LYRA : NSDQ)
 
 • Company Description   
Lyra Therapeutics Inc. is a clinical-stage therapeutics company. It is focused on the development and commercialization of novel integrated drug and delivery solutions for patients with ear, nose and throat diseases. The company's proprietary technology platform, XTreo(TM), is designed to precisely and consistently deliver medicines directly to the affected tissue. Its initial product candidates consist LYR-210 and LYR-220 which are in clinical stage. Lyra Therapeutics Inc. is based in Watertown, Mass.

Number of Employees: 38

 
 • Price / Volume Information   
Yesterday's Closing Price: $8.44 Daily Weekly Monthly
20 Day Moving Average: 194,164 shares
Shares Outstanding: 13.00 (millions)
Market Capitalization: $109.73 (millions)
Beta:
52 Week High: $16.50
52 Week Low: $6.85
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 16.58% 15.31%
12 Week -27.18% -31.80%
Year To Date -25.97% -34.44%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
480 ARSENAL STREET
-
WATERTOWN,MA 02472
USA
ph: 617-373-4600
fax: -
laurence@gilmartinir.com http://www.lyratherapeutics.com
 
 • General Corporate Information   
Officers
Maria Palasis - President and Chief Executive Officer
Michael Altman - Director
Edward Anderson - Director
C. Ann Merrifield - Director
Konstantin Poukalov - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 55234L105
SIC: 3841
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/21
Next Expected EPS Date: 08/04/21
Share - Related Items
Shares Outstanding: 13.00
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $109.73 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.61 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.31 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/21  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.62
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 96.79%
vs. Previous Quarter: -30.43%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/21 - -33.18
12/31/20 - -76.67
09/30/20 - -
ROA
03/31/21 - -30.79
12/31/20 - -29.34
09/30/20 - -33.01
Current Ratio
03/31/21 - 16.15
12/31/20 - 15.54
09/30/20 - 17.75
Quick Ratio
03/31/21 - 16.15
12/31/20 - 15.54
09/30/20 - 17.75
Operating Margin
03/31/21 - -
12/31/20 - -
09/30/20 - -
Net Margin
03/31/21 - -
12/31/20 - -
09/30/20 - -
Pre-Tax Margin
03/31/21 - -
12/31/20 - -
09/30/20 - -
Book Value
03/31/21 - 5.21
12/31/20 - 5.76
09/30/20 - 6.26
Inventory Turnover
03/31/21 - -
12/31/20 - -
09/30/20 - -
Debt-to-Equity
03/31/21 - 0.00
12/31/20 - 0.00
09/30/20 - 0.00
Debt-to-Capital
03/31/21 - 0.00
12/31/20 - 0.00
09/30/20 - 0.00
 

Powered by Zacks Investment Research ©